This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Trial of efficacy of synthetic vs. animal surfactant

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

GESTATION: A RAMDOMISED TRIAL

The trial compared the efficacy of a synthetic surfactant (Pumactant) and an animal-derived surfactant (Poractant alfa) in premature neonates with respiratory distress syndrome.

The primary end-point was duration of high-dependency care. The secondary end-point was mortality.

Reference:

  • 1) Ainsworth, SB, Beresford, MW. et al. (2000). Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet, 355, 1387-92

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.